Enzyme News and Research

RSS

DFG approves establishment of twelve new CRCs

The Deutsche Forschungsgemeinschaft has approved the establishment of twelve new Collaborative Research Centres beginning 1 July 2010. This was decided by the responsible Grants Committee at its spring meeting in Bonn. The new CRCs will initially be funded for four years with a total of 112 million euros (including a 20% programme allowance for indirect project costs).

29 May 2010

Life Technologies acquires majority stake in Geneart

Life Technologies Corporation, a provider of innovative life science solutions, announced today that it has concluded its tender offer and acquired a majority stake in Geneart AG, the global leader of the synthetic gene market segment. The combination of Geneart with Life Technologies' resources and commercial capabilities creates a well-capitalized synthetic biology company with advanced technology and production capabilities, providing products to fuel innovation in this emerging field.

28 May 2010

Thermo Fisher Scientific to acquire Fermentas International for $260M

Thermo Fisher Scientific Inc., the world leader in serving science, announced today that it has signed a definitive agreement to acquire Fermentas International Inc. - a manufacturer and global distributor of enzymes, reagents and kits for molecular and cellular biology research - for $260 million in cash, subject to a post-closing adjustment. With headquarters in Burlington, Ontario, and principal operations in Vilnius, Lithuania, Fermentas has approximately 500 employees.

From Thermo Fisher Scientific Inc. 28 May 2010

PCA-Rx represents next generation of chelation technology for ASD patients

According to the Center for Disease Control, autism has risen to an epidemic rate of 1 in 100 in the U.S., up from 1 in 150 in 2007. While controversy looms regarding its cause, many parents of autistic children believe a correlation exists with toxin accumulation. To give autism spectrum disorder sufferers a natural alternative to chelation therapy, Maxam Nutraceutics has introduced PCA-Rx.

28 May 2010

UCSF research shows brief exercise buffers the effects of stress-induced cell aging

Exercise can buffer the effects of stress-induced cell aging, according to new research from UCSF that revealed actual benefits of physical activity at the cellular level.

27 May 2010

Drug and dosage influence risk of GI bleeding

A study conducted at the Spanish Centre for Pharmacoepidemiological Research revealed that the risk of gastrointestinal complications due to nonsteroidal anti-inflammatory drug (NSAID) use varies by specific NSAID administered and by dosage. The study further determined that NSAIDs with a long half-life or slow-release formulation are associated with a greater risk of GI bleeding or perforation.

27 May 2010

Researchers use new imaging technique to view microvessels in the brains of living mice

Researchers at Northwestern University Feinberg School of Medicine have identified in mice a previously unknown protective mechanism by which the smallest blood vessels remove blood clots and other blockages from the brain. The findings provide insights into mechanisms that may be involved in age-related cognitive decline, Alzheimer's disease and recovery from stroke.

27 May 2010

Good number of natural bypass vessels an 'insurance policy' against blockage

When the arteries delivering oxygen to our vital organs are obstructed by atherosclerosis or clots, the result is almost always a stroke, heart attack or damage to a peripheral tissue such as the legs (peripheral artery disease). But the severity of tissue injury or destruction from a choked-off blood supply varies from person to person, and may depend in large part on whose circulatory system has the best back-up plan to provide alternate routes of circulation.

26 May 2010

UT Southwestern Medical Center researchers identify novel chemical compounds with anti-malarial activity

As part of a multicenter study, UT Southwestern Medical Center researchers have identified a series of chemical compounds that might serve as starting points for the identification of new classes of anti-malarial drugs.

26 May 2010

Increasing levels of GGA3 protein prevent accumulation of enzyme linked to Alzheimer's disease

Researchers at Tufts University School of Medicine have zeroed in on a protein that may play a role in the progression of Alzheimer's disease. The team found that increasing levels of the protein (called GGA3) prevented the accumulation of an enzyme linked to Alzheimer's. The strategy may lead to new treatments for the neurodegenerative disease.

26 May 2010

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

Vertex Pharmaceuticals Incorporated today announced that 75% of people chronically infected with genotype 1 hepatitis C virus (HCV) who had not previously been treated achieved a sustained viral response (SVR or viral cure) after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial.

26 May 2010

Lumizyme receives FDA approval for patients with late-onset Pompe disease

The U.S. Food and Drug Administration approved Lumizyme (alglucosidase alfa) for patients ages 8 years and older with late-onset (non-infantile) Pompe disease, a rare genetic disorder.

26 May 2010

Genzyme's Lumizyme for Pompe disease receives FDA marketing approval

Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.

25 May 2010

Spectrum Pharmaceuticals to present clinical data on belinostat at ASCO 2010

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in hematology and oncology, today announced that clinical data on belinostat will be presented at the 2010 Annual Meeting of the American Society of Clinical Oncology, to be held June 4-8, 2010 at the McCormick Place Convention Center in Chicago, Illinois.

25 May 2010

Clovis Oncology, Avila Therapeutics announce development agreement for NSCLC EMSI program

Clovis Oncology, Inc., a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents, and Avila Therapeutics, Inc., a biotechnology company designing targeted covalent drugs, announced today an agreement for the development and commercialization of Avila's epidermal growth factor receptor (EGFR) mutant-selective inhibitor (EMSI) program, currently in pre-clinical development for the treatment of non-small cell lung cancer (NSCLC).

25 May 2010

Yissum introduces Dralgo platform to accelerate discovery of promising drug candidates

Drug discovery and development is a highly risky process, with only one in 10,000 initial candidate compounds reaching the market. When taking into account the aborted candidates, the cost of developing one successful drug may even reach $1 billion, and the development process may take as long as 15-20 years.

25 May 2010

Genzyme signs consent decree of permanent injunction, agrees to disgorgement

Genzyme Corp. has signed a consent decree agreeing to correct manufacturing quality violations at its Allston, Mass., manufacturing facility and will turn over to the federal government $175 million in unlawful profits from the sale of products that were made at the plant, the U.S. Food and Drug Administration announced today.

25 May 2010

ADDF provides $248,000 grant to ALSP to allow its lead drug candidate towards clinical trials

The Alzheimer's Drug Discovery Foundation announced today that it is providing a grant of $248,000 to American Life Science Pharmaceuticals, Inc. to allow for manufacture of its lead drug candidate to be used in preclinical toxicology testing in preparation for entering Phase I clinical trials early in 2011.

25 May 2010

Abbott's new FreeStyle Lite blood glucose test strips receive FDA clearance

Abbott today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration for its new FreeStyle Lite blood glucose test strips. The new FreeStyle Lite test strips minimize interference during blood glucose testing and are designed to offer a better testing experience.

24 May 2010

ZyGEM announces acquisition of MicroLab Diagnostics

ZyGEM Corp. Ltd., today announced that it has acquired MicroLab Diagnostics Inc., a private company developing microfluidic devices for rapid DNA testing. ZyGEM intends to market products integrating its unique DNA extraction and reagents and detection assays with the breakthrough microfluidic chip technology developed by MicroLab, which will operate as a business unit of the new company.

24 May 2010

Enzyme News and Research

DFG approves establishment of twelve new CRCs

Life Technologies acquires majority stake in Geneart

Thermo Fisher Scientific to acquire Fermentas International for $260M

PCA-Rx represents next generation of chelation technology for ASD patients

UCSF research shows brief exercise buffers the effects of stress-induced cell aging

Drug and dosage influence risk of GI bleeding

Researchers use new imaging technique to view microvessels in the brains of living mice

Good number of natural bypass vessels an 'insurance policy' against blockage

UT Southwestern Medical Center researchers identify novel chemical compounds with anti-malarial activity

Increasing levels of GGA3 protein prevent accumulation of enzyme linked to Alzheimer's disease

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

Lumizyme receives FDA approval for patients with late-onset Pompe disease

Genzyme's Lumizyme for Pompe disease receives FDA marketing approval

Spectrum Pharmaceuticals to present clinical data on belinostat at ASCO 2010

Clovis Oncology, Avila Therapeutics announce development agreement for NSCLC EMSI program

Yissum introduces Dralgo platform to accelerate discovery of promising drug candidates

Genzyme signs consent decree of permanent injunction, agrees to disgorgement

ADDF provides $248,000 grant to ALSP to allow its lead drug candidate towards clinical trials

Abbott's new FreeStyle Lite blood glucose test strips receive FDA clearance

ZyGEM announces acquisition of MicroLab Diagnostics

Measuring Drug-Target Residence Times with Biochemical Assays eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo